Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Treatment of overactive bladder with modified intravesical oxybutynin chloride
Autore:
Saito, M; Tabuchi, F; Otsubo, K; Miyagawa, I;
Indirizzi:
Tottori Univ, Fac Med, Dept Urol, Yonago, Tottori 6830826, Japan Tottori Univ Yonago Tottori Japan 6830826 Yonago, Tottori 6830826, Japan Tottori Univ Hosp, Div Pharma, Yonago, Tottori, Japan Tottori Univ Hosp Yonago Tottori Japan iv Pharma, Yonago, Tottori, Japan
Titolo Testata:
NEUROUROLOGY AND URODYNAMICS
fascicolo: 6, volume: 19, anno: 2000,
pagine: 683 - 688
SICI:
0733-2467(2000)19:6<683:TOOBWM>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
DETRUSOR HYPERREFLEXIA; NEUROGENIC BLADDER; CHILDREN;
Keywords:
intravesical oxybutynin chloride; overactive bladder; hydroxypropylcellulose;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
14
Recensione:
Indirizzi per estratti:
Indirizzo: Saito, M Tottori Univ, Fac Med, Dept Urol, 86 Nishimachi, Yonago, Tottori 6830826, Japan Tottori Univ 86 Nishimachi Yonago Tottori Japan 6830826 26, Japan
Citazione:
M. Saito et al., "Treatment of overactive bladder with modified intravesical oxybutynin chloride", NEUROUROL U, 19(6), 2000, pp. 683-688

Abstract

Intravesical oxybutynin chloride has been reported to be effective for overactive bladder, although sometimes the efficacy does not last long enough. To improve this deficiency, we report the effects of intravesical oxybutynin chloride with hydroxypropylcellulose (modified intravesical oxybutynin). Modified intravesical oxybutynin (5 mg/10 mt, twice a day) was administered to six overactive bladder patients for more than 1 year (two men and foulwomen; average age, 56.5 years) who did not respond to oral anticholinergic agents and electric stimulation. Cystometography (CMG) was performed before, 2 hours, and 1 week after the start of modified intravesical oxybutynin. In addition, plasma levels of oxybutynin and its active metabolite, N-desethyl-oxybutynin (DEOB), were measured by high-performance liquid chromatography before, 1, 2, and 4 hours after the initial treatment of modified intravesical oxybutynin. CMG studies revealed that two of the six patients didnot demonstrate uninhibited contractions 1 week after the treatment and that cystocapacity of before, 2 hours, and 1 week after the initial modified intravesical oxybutynin was 141.8 +/- 15.3, 210.0 +/- 35.5, and 305.0 +/- 21.3 mL, respectively. Plasma levels of oxybutynin and DEOB before, 1, 2, and 4 hours after the first instillation of modified intravesical oxybutynin were oxybutynin; not detected, 8.8 +/- 2.5, 6.8 +/- 1.1, 3.0 +/- 1.0 ng/ml,and DEOB: not detected, 4.2 +/- 1.3, 6.4 +/- 1.7, 5.1 +/- 1.4 ng/ml, respectively. No side effects were observed in any of the patients. Modified intravesical oxybutynin is an effective and safe therapy option for overactivebladder patients who do not respond to other treatments such as oral anticholinergic agents and electric stimulation. (C) 2000 Wiley-Liss. Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/09/20 alle ore 23:47:04